Pharmaceutical

China’s NMPA approves Antengene’s XPOVIO for DLBCL

China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.

Jul 10, 2024 - 04:00
China’s NMPA approves Antengene’s XPOVIO for DLBCL
China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.
Read the original article

Tags:

Previous Article

UK pharma group reprimands Novo Nordisk for undisclosed payments

Next Article

Mesoblast Resubmits BLA For Ryoncil Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: What comes after Wegovy? The quest to eradicate obesity

STAT+: What comes after Wegovy? The quest to eradicate ...

Dec 27, 2023

STAT+: Early findings in gene therapy death suggest CRISPR was not the cause

STAT+: Early findings in gene therapy death suggest CRI...

Apr 27, 2023

STAT+: Dana-Farber’s divorce from Brigham is the culmination of decades of change

STAT+: Dana-Farber’s divorce from Brigham is the culmin...

Oct 16, 2023